Published Research

Perfluorocarbon Emulsions as a Promising Technology: A Review of Tissue and Vascular Gas Dynamics
Journal of Applied Physiology

Perfluorocarbon Emulsions Improve Cognitive Recovery After Lateral Fluid Percussion Brain Injury In Rats
Neurosurgery

Reduction of hypoxia by perfluorocarbon emulsion in a traumatic spinal cord injury model
J. Neurosurg.: Spine

Perfluorocarbon Emulsion does not Impact Coagulation and Platelet Function in vitro
Poster Presentation

Safety and efficacy of Early Administration of the Perfluorocarbon OXYCYTE to Improve Cerebral Oxygenation after Severe Traumatic Brain Injury
Poster Presentation

 

  • Funds breathe new life into Oxygen Biotherapeutics

By DAVID RANII
Posted on Wednesday, Jan. 25, 2012

After a tumultuous year that featured the dismissal of its CEO, drug-development company Oxygen Biotherapeutics is starting 2012 in its best financial shape in years.
The small, publicly traded Morrisville company turned a financial corner at the end of last year when it sold $7.5 million in preferred stock and warrants to institutional investors. The company received $3.5 million in December, with the second installment expected midyear.

In the past, Oxygen Bio has raised money that would carry it forward for about six months, but this was a richer deal. More...

Quick Links